Home' Australian Pharmacist : Australian Pharmacist January 2013 Contents Australian Pharmacist January 2013 I ©Pharmaceutical Society of Australia Ltd. 67
Continuing Professional Development
Submit your answers online before
1 March 2013 at www.psa.org.au and
receive automatic feedback, or NZ
members can fax/mail to:
NZCP CPD answers,
PO Box 11 640, Wellington
Fax: (04) 381 4786
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA's
CPD&PI program. It is also part of the New Zealand
College of Pharmacists (NZCP) education program
for NZ pharmacists.
The CPD section is recognised under the PSA
CPD&PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer. The credits allocated to
each section and the pass mark are shown with
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions,
4 out of 5 questions, or 3 out of 4 questions correct is
required for the allocation of Group 2 CPD Credits.
PSA members can answer online at
www.psa.org.au and receive automatic feedback.
• You will need to login to submit your answers
online. If you do not have member access
details, you can request them via a link from
the login page.
• Select Pharmacist Members from the blue, left
hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
61. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric
acid crystals activate the NALP3 inflammasome. Nature
62. Sivera F, Wechalekar M, Andres M, et al. Interleukin-1 inhibitors
for acute gout. Cochrane Database of Systematic Reviews
2012, Issue 7. Art. No.: CD009993. DOI: 10.1002/14651858.
63. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American
College of Rheumatology guidelines for management of gout.
Part 1: Systematic nonpharmacologic and pharmacologic
therapeutic approaches to hyperuricemia. Arthritis Care Res
64. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle
modifications for gout. Arthritis Res Ther 2006;8 Suppl 1:S2.
65. Zhang Y, Chen C, Choi H, et al. Purine-rich foods intake and
recurrent gout attacks. Ann Rheum Dis 2012;71(9):1448--53.
66. Choi HK, Willett W, Curhan G. Coffee consumption and risk of
incident gout in men: a prospective study. Arthritis Rheum
67. Rossi S. Australian Medicines Handbook. Adelaide: AMH; 2012.
68. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor
for allopurinol hypersensitivity syndrome: a proposed safe
starting dose of allopurinol. Arthritis Rheum 2012;64(8):2529--36.
69. Becker MA, MacDonald PA, Hunt BJ, et al. Determinants of
the clinical outcomes of gout during the first year of urate-
lowering therapy. Nucleosides Nucleotides Nucleic Acids
70. Neogi T. Clinical practice. Gout. New Engl J Med
71. Perez-Ruiz F, Atxotegi J, Hernando I, et al. Using serum urate
levels to determine the period free of gouty symptoms after
withdrawal of long-term urate-lowering therapy: a prospective
study. Arthritis Rheum 2006;55(5):786--90.
72. Perez-Ruiz F. Treating to target: a strategy to cure gout.
Rheumatol (Oxford) 2009;48 Suppl 2:ii9-ii14.
73. National Institute for Health and Clinical Excellence. Febuxostat
for the management of hyperuricaemia in people with gout.
74. National Institute for Health and Clinical Excellence.
Pegloticase for the treatment of hyperuricaemia in people with
symptomatic gout refractory to conventional urate-lowering
75. Richette P, Briere C, Hoenen-Clavert V, et al. Rasburicase for
tophaceous gout not treatable with allopurinol: an exploratory
study. J Rheumatol 2007;34(10):2093--8.
76. Richette P, Bardin T. Successful treatment with rasburicase of
a tophaceous gout in a patient allergic to allopurinol. Nat Clin
Pract 2006;2(6):338--42; quiz 43.
77. Burns CM, Wortmann RL. Gout therapeutics: new drugs for an
old disease. Lancet 2011;377(9760):165--77.
78. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis
of acute flares when initiating allopurinol for chronic gouty
arthritis. J Rheumatol 2004;31(12):2429--32.
79. Wortmann RL, Macdonald PA, Hunt B, et al. Effect of
prophylaxis on gout flares after the initiation of urate-lowering
therapy: analysis of data from three phase III trials. Clin Ther
80. Hak AE, Choi HK. Lifestyle and gout. Curr Opin Rheumatol
81. Lee SJ, Terkeltaub RA, Kavanaugh A. Recent developments in
diet and gout. Curr Opin Rheumatol 2006;18(2):193--8.
Australians under the age of 30 are
experiencing serious but preventable
long-term complications of diabetes
according to the Australian Institute
of Health and Welfare (AIHW) report,
Diabetes among young Australians.
The report found that young adults may
not be monitoring and managing their
diabetes as well as possible. It explores
how young Australians (0--30 years) with
diabetes are managing their condition,
their use of health services, and the
diabetes-related health problems
It says that in 2010, about 31,300
young Australians with diabetes were
registered with the National Diabetes
Services Scheme. Most (79%) had type
1 diabetes -- a lifelong autoimmune
disease that requires the administration
of insulin many times a day for
survival. Monitoring blood glucose
levels is an important part of diabetes
management, particularly for those with
Type 1 diabetes and on insulin.
AIHW spokesperson Susana Senes said:
'The good news is that on average,
enough blood glucose testing strips
were bought for children with Type
1 diabetes aged 0--11 years to meet
recommended daily testing levels.
'Similarly, people with Type 1 diabetes
using an insulin pump generally
purchased enough testing strips.'
However, there is room for improvement.
The report shows that people aged 19--24
with both Type 1 and Type 2 diabetes
bought blood glucose test strips at lower
rates than other age groups, suggesting
that they are not monitoring their
diabetes as well as others.
In 2009--10, there were about 15,500
diabetes-related hospitalisations among
young Australians. Children aged 0--11
had the highest rate of hospitalisation for
Type 1 diabetes but these were mainly for
stabilising diabetes, being diagnosed with
diabetes or for fitting an insulin pump.
People under 25 were hospitalised more
often than those aged 25--30 for acute
diabetes-related complications, such as
ketoacidosis. Admissions for ketoacidosis
have been increasing, and are often
associated with non-compliance with
medical treatment among those aged
12--18, and to a lesser extent in those
'Some young people aged 19--30
are already experiencing serious but
preventable long-term complications
of diabetes, including nerve damage,
foot ulcers, eye and kidney disease.
In 2009--10, among people with
Type 1 diabetes aged 25--30, there
were 58 hospitalisations for long-term
complications of diabetes per 1,000
women and 32 per 1,000 men.'
Diabetes was the main cause of death of
88 people aged 0--30, and an associated
cause for a further 76 between 2001 and
2007. Most were in people aged 25-30.
EVIDENCE IN PATIENT CARE
Links Archive Australian Pharmacist December 2012 February 2013 Navigation Previous Page Next Page